Vision loss relentless in advanced AMD patients

Article

Patients who develop advanced age-related macular degeneration (AMD) undergo a precipitous loss of vision, concluded the researchers of this study recently published in the Journal of the American Medical Association Ophthalmology.

Patients who develop advanced age-related macular degeneration (AMD) undergo a precipitous loss of vision, concluded the researchers of this study recently published in the Journal of the American Medical Association Ophthalmology.

Researchers from the National Eye Institute, EMMES Corporation, and the University of Wisconsin followed up on 3,549 patients from the Age-Related Eye Disease Study (AREDS) for an additional 5 years after the initial trial of antioxidant vitamins and minerals was finished. Patients in the initial trial were aged 55 to 80 years and were followed for a median of 6.5 years.

Researchers noted the development of the varying stages of age-related macular degeneration in patients and changes in visual acuity. In addition, they measured the rates of progression to large drusen and advanced AMD with annual fundus photographs assessed centrally. BCVA was also measured annually.

The risk of progression to advanced AMD increased with increasing age (P = 0.01) and severity of drusen. Women and current smokers had an increased risk of neovascular AMD (P = 0.005 and P

Rates of progression to large drusen increased with an increased severity of baseline drusen; a full 70.9% of patients with bilateral medium drusen progressed to large drusen, and 13.8% to advanced AMD in 10 years. Median visual acuity at 10 years in eyes with large baseline drusen who never developed advanced AMD was 20/25. In eyes that did develop advanced AMD, median visual acuity was 20/200.

To read the abstract of this study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.